Role of AT1 receptor-mediated salt retention in angiotensin II-dependent hypertension

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 5, 2011, Pages

  Crowley, Steven D ^a   Zhang, Jiandong ^a   Herrera, Maria ^a   Griffiths, Robert ^a   Ruiz, Phillip ^b   Coffman, Thomas M ^a  

^a DURHAM VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Kidney diseases

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; SPIRONOLACTONE; ALDOSTERONE ANTAGONIST; INORGANIC SALT;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MALE; MICROCIRCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SODIUM RETENTION; 129 MOUSE; ANIMAL; BLOOD PRESSURE; C57BL MOUSE; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; KIDNEY; METABOLISM; PATHOLOGY; PHYSIOLOGY; RENOVASCULAR HYPERTENSION; SODIUM RESTRICTION;

ALBUMINURIA; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; DIET, SODIUM-RESTRICTED; DISEASE PROGRESSION; HYPERTENSION, RENAL; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; RECEPTOR, ANGIOTENSIN, TYPE 1; SALTS;

EID: 80055099871     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00305.2011     Document Type: Article

References (27)

1. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F, Takeuchi K, Ito S. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14: 2255-2263, 2003.
2. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 44: 595-601, 2004.
3. Bidani AK, Griffin KA, Picken M, Lansky DM. Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant kidney model. Am J Physiol Renal Fluid Electrolyte Physiol 265: F391-F398, 1993.
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
5. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219-1227, 2000.
6. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286: 441-449, 1972.
7. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Doubleblind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1: 256-262, 2006.
8. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 103: 17985-17990, 2006.
9. Crowley SD, Gurley SB, Oliverio MI, Pazmino AK, Griffiths R, Flannery PJ, Spurney RF, Kim HS, Smithies O, Le TH, Coffman TM. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest 115: 1092-1099, 2005.
10. Crowley SD, Song YS, Sprung G, Griffiths R, Sparks M, Yan M, Burchette JL, Howell DN, Lin EE, Okeiyi B, Stegbauer J, Yang Y, Tharaux PL, Ruiz P. A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension 55: 99-108, 2010.
11. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003, 2002.
12. Davisson RL, Oliverio MI, Coffman TM, Sigmund CD. Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest 106: 103-106, 2000.
13. Francois H, Athirakul K, Mao L, Rockman H, Coffman TM. Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension 43: 364-369, 2004.
14. Gavras H, Lever AF, Brown JJ, Macadam RF, Robertson JI. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 2: 19-22, 1971.
15. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: 1063-1068, 1996.
16. Griffin KA, Abu-Amarah I, Picken M, Bidani AK. title typecontributorRenoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 41: 201-206, 2003.
17. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 1: 1054-1065, 2006.
18. Henke N, Schmidt-Ullrich R, Dechend R, Park JK, Qadri F, Wellner M, Obst M, Gross V, Dietz R, Luft FC, Scheidereit C, Muller DN. Vascular endothelial cell specific NF-_B suppression attenuates hypertension- induced renal damage. Circ Res 101: 268-276, 2007.
19. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92: 3521-3525, 1995.
20. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
21. Marvar PJ, Thabet SR, Guzik TJ, Lob HE, McCann LA, Weyand C, Gordon FJ, Harrison DG. Central and peripheral mechanisms of T-ymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res 107: 263-270, 2010.
22. Michel F, Ambroisine ML, Duriez M, Delcayre C, Levy BI, Silvestre JS. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation 109: 1933-1937, 2004.
23. Morris M, Li P, Callahan MF, Oliverio MI, Coffman TM, Bosch SM, Diz DI. Neuroendocrine effects of dehydration in mice lacking the angiotensin AT1a receptor. Hypertension 33: 482-486, 1999.
24. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237, 1999.
25. Spurney RF, Ibrahim S, Butterly D, Klotman PE, Sanfilippo F, Coffman TM. Leukotrienes in renal transplant rejection in rats. Distinct roles for leukotriene B4 and peptidoleukotrienes in the pathogenesis of allograft injury. J Immunol 152: 867-876, 1994.
26. Spurney RF, Ruiz P, Pisetsky DS, Coffman TM. Enhanced renal leukotriene production in murine lupus: role of lipoxygenase metabolites. Kidney Int 39: 95-102, 1991.
27. van Kats JP, Methot D, Paradis P, Silversides DW, Reudelhuber TL. Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice. Direct and indirect effects of angiotensin II on the heart. J Biol Chem 276: 44012-44017, 2001.